KalshiScience and Technology
When will the FDA approve Compass Pathways' COMP360 Psilocybin?
COMP360 Psilocybin for Treatment-Resistant Depression
Ends Jan 1, 2027
Bet NowDisclosure
18+ only. Event contracts carry significant risk and are not suitable for everyone, you can lose the entire amount you commit. Not available in all jurisdictions; restrictions and eligibility requirements apply.
Probability
- Before Jan 1, 20274.2K VOL.Yes 30%No 70%30¢
- Before Mar 1, 20272K VOL.Yes 53%No 47%53¢
- Before July 20278.6K VOL.Yes 86%No 14%86¢
- Before October 20272.3K VOL.Yes 90%No 10%90¢
- Before 20281.1K VOL.Yes 92%No 8%92¢
Rules Summary
If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2027, then the market resolves to Yes.
Timeline and Payout
- Opened
- May 16, 2026, 2:30 AM
- Closes
- Jan 1, 2027, 4:59 AM
- Pays out
- 0.5 hours after close
Series KXFDAAPPROVALDATECMPS · Event KXFDAAPPROVALDATECMPS-360 · Market KXFDAAPPROVALDATECMPS-360-27JAN01

